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ABSTRACT
Objective To compare rates of necrotising enterocolitis 
(NEC), late- onset sepsis, and mortality in 5- year epochs 
before and after implementation of routine daily multistrain 
probiotics administration in high- risk neonates.
Design Single- centre retrospective observational study 
over the 10- year period from 1 January 2008 to 31 
December 2017.
Setting Level 3 neonatal intensive care unit (NICU) of 
the Norfolk and Norwich University Hospital, UK.
Patients Preterm neonates at high risk of NEC: 
admitted to NICU within 3 days of birth at <32 weeks’ 
gestation or at 32–36 weeks’ gestation and of birth 
weight <1500 g.
Intervention Prior to 1 January 2013 probiotics 
were not used. Thereafter, dual- species Lactobacillus 
acidophilus and Bifidobacterium bifidum combination 
probiotics were routinely administered daily to high- 
risk neonates; from April 2016 triple- species probiotics 
(L. acidophilus, B. bifidum, and B. longum subspecies 
infantis) were used.
Main outcome measures Incidence of NEC (modified 
Bell’s stage 2a or greater), late- onset sepsis, and 
mortality.
Results Rates of NEC fell from 7.5% (35/469 neonates) 
in the pre- implementation epoch to 3.1% (16/513 
neonates) in the routine probiotics epoch (adjusted 
sub- hazard ratio=0.44, 95% CI 0.23 to 0.85, p=0.014). 
The more than halving of NEC rates after probiotics 
introduction was independent of any measured 
covariates, including breast milk feeding rates. Cases of 
late- onset sepsis fell from 106/469 (22.6%) to 59/513 
(11.5%) (p<0.0001), and there was no episode of 
sepsis due to Lactobacillus or Bifidobacterium. All- cause 
mortality also fell in the routine probiotics epoch, from 
67/469 (14.3%) to 47/513 (9.2%), although this was 
not statistically significant after multivariable adjustment 
(adjusted sub- hazard ratio=0.74, 95% CI 0.49 to 1.12, 
p=0.155).
Conclusions Administration of multispecies 
Lactobacillus and Bifidobacterium probiotics has been 
associated with a significantly decreased risk of NEC 
and late- onset sepsis in our neonatal unit, and no safety 
issues. Our data are consistent with routine use of 
Lactobacillus and Bifidobacterium combination probiotics 
having a beneficial effect on NEC prevention in very 
preterm neonates.
InTRODuCTIOn
Necrotising enterocolitis (NEC) is a leading cause 
of mortality and morbidity in premature very low 
birthweight (VLBW; <1500 g) babies.1 2 Prevention 
of NEC is a top UK research priority.3 NEC aeti-
ology is multifactorial,4 with abnormal gut micro-
biota increasingly recognised as central.5 Probiotics 
are ‘live microorganisms that, when administered 
in adequate amounts, confer a health benefit on 
the host’.6 Multiple randomised controlled trials 
(RCTs), systematic reviews and meta- analyses of 
RCTs and observational studies have shown that 
prophylactic probiotics prevent NEC in preterm 
babies.7–9 A 2012 meta- analysis,10 updated in 2017 
to include 25 RCTs and >7000 neonates,11 showed 
strong evidence for using multispecies probiotics to 
reduce NEC incidence (pooled OR=0.36, 95% CI 
What is already known on this topic?
 ► Necrotising enterocolitis (NEC) remains a 
leading cause of mortality and morbidity in 
premature and very low birthweight infants.
 ► The aetiology of NEC is multifactorial, but the 
development of an abnormal gut microbiota is 
an important predisposing risk factor.
 ► Multiple meta- analyses and observational 
studies have shown that ameliorating gut 
bacterial colonisation through the enteral 
administration of live probiotic bacteria 
significantly reduces NEC incidence.
What this study adds?
 ► Routine daily dosing with Lactobacillus and 
Bifidobacterium probiotics was a cheap, simple 
intervention associated with significantly 
decreased NEC, surgical NEC and late- onset 
sepsis in our neonatal unit.
 ► No episode of sepsis due to Lactobacillus 
or Bifidobacterium occurred in the routine 
probiotic supplementation epoch.
 ► The apparent impact of reduced NEC incidence 
with probiotics was particularly pronounced 
in the first 2 weeks postnatal, implying 
that achieving early probiotic bacterial gut 
colonisation is crucial.
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Table 1 NEC incidence and severity, sepsis incidence, and baseline 
data in the pre- probiotics vs routine probiotics epochs
Factor
Pre- probiotics epoch 
n=469
Routine probiotics 
epoch n=513
NEC diagnostic system
  Modified Bell’s ≥2a 35 (7.5%) 16 (3.1%)
  Vermont- Oxford 30 (6.4%) 15 (2.9%)
  Battersby et al 37 (7.9%) 19 (3.7%)
NEC severity
  Modified Bell’s 2a or 2b 6 (1.3%) 2 (0.4%)
  Modified Bell’s 3a or 3b 29 (6.2%) 14 (2.7%)
Surgical NEC 30 (6.4%) 15 (2.9%)
  Drains only 4 1
  Laparotomy±drain 20 13
  Died before laparotomy 6 1
Postnatal age at NEC diagnosis (days) 12 (6–21) 18 (11–30)
Postmenstrual age at NEC diagnosis (weeks) 27 (26–29) 28 (26–31)
Mortality before discharge among NEC cases 16 (46%) 3 (19%)
Spontaneous intestinal perforation 2 (0.4%) 6 (1.1%)
Sepsis
  Early onset sepsis 10 (1.1%) 1 (0.2%)
  Late- onset sepsis 106 (22.6%) 59 (11.5%)
  Responsible isolates*
   CoNS 87 (18.6%) 47 (9.2%)
   Gram- negative 19 (4.1%) 6 (1.2%)
   Enterococcus 11 (2.3%) 2 (0.4%)
   Other organism 15 (3.2%) 6 (1.2%)
   Lactobacillus or Bifidobacterium sepsis 0 (0%) 0 (0%)
Sex, female 225 (48%) 261 (51%)
Mode of delivery
  Vaginal 193 (42%) 229 (45%)
  Caesarean 271 (58%) 284 (55%)
PROM
  No 306 (65%) 347 (68%)
  Yes 103 (22%) 118 (23%)
  Not recorded 60 (13%) 48 (9%)
NSAID treatment for PDA
  None 421 (90%) 487 (95%)
  Indometacin 37 (8%) 0 (0%)
  Ibuprofen 11 (2%) 26 (5%)
Birth weight (g) 1100 (810–1410) 1100 (832–1430)
Gestational age (weeks) 28 (26–30) 28 (26–31)
SGA 114 (24%) 132 (26%)
Antenatal steroids 405 (87%) 447 (88%)
Received initial antibiotics† 502/599 (83.8%) 509/597 (85.6%)
Days to first enteral feed 2 (1–4) 2 (2–3)
Enteral feeding‡
  Never fed 34 (7%) 32 (6%)
  Mother’s own breast milk only 198 (42%) 322 (63%)
  Donor breast milk only 0 (0%) 9 (2%)
  Preterm formula only 50 (11%) 23 (4%)
  Mixed (formula and any breast milk) 186 (40%) 127 (25%)
Data are median (IQR) or number (%).
*For individual infants who had at least one such sepsis episode.
†Data presented are for all babies born at <32 weeks’ gestation within the epochs who received initial 
empirical antibiotics (benzylpenicillin and gentamicin) following admission to NICU.
‡Mode of milk feeding between first feed and full feeds or NEC/death if earlier.
PDA, patent ductus arteriosus; CoNS, coagulase- negative staphylococci;NEC, necrotising enterocolitis; 
NICU, neonatal intensive care unit; NSAID, non- steroidal anti- inflammatory drug; PROM, prolonged 
rupture of membranes;SGA, small for gestational age.
0.24 to 0.53, p<0.00001), and associated mortality (OR=0.58, 
95% CI 0.43 to 0.79, p=0.0006). Yet at present most UK centres 
do not offer probiotics routinely.12 Uncertainties about effec-
tiveness may arise from RCTs which have not shown benefit, 
heterogeneity, multiplicity, and dosage of probiotic microorgan-
isms, differing inclusion criteria, treatment durations and NEC 
definitions used to assess benefit.13
There are no published reports on the safety or efficacy of 
routine probiotics used in any UK centres. We therefore aimed to 
assess whether routine probiotic supplementation has been asso-
ciated with a decreased incidence of NEC, sepsis, and all- cause 
mortality in our centre.
MeThODS
Single- centre retrospective review of neonates admitted to our 
tertiary- level neonatal intensive care unit (NICU) which caters 
to ~6000 deliveries annually and is a regional neonatal surgical 
centre.
eligible population
‘Eligible high- risk neonates’ comprised all those inborn at <32 
weeks’ gestation, plus 32–36 weeks’ gestation VLBW infants. 
Outborn babies were included if transferred in within 72 hours 
of birth, providing no abdominal concerns at referral.
Study period
Eligible neonates were reviewed in two consecutive 5- year 
epochs, allocated by date of birth: 1 January 2008 to 31 
December 2012 (pre- probiotics epoch) and 1 January 2013 to 
31 December 2017 (routine probiotic epoch).
enteral feeding practices
Our unit adopted a standardised regional enteral feeding guide-
line for preterm neonates in January 2011. Ideally, human milk 
feeds commenced on day 1. From May 2013, donor breast milk 
(DBM) was available to supplement shortfalls in mother’s own 
breast milk supply before full feeds. Cow’s milk- based fortifier 
was added to breast milk between full enteral feeds (≥150 mL/
kg/day) and discharge—a consistent policy across epochs. Milk 
type used in the period until full feeds was categorised as exclu-
sive maternal breast milk, exclusive DBM, formula, or mixed (ie, 
any combination of own maternal milk, DBM, and formula).
Probiotic exposure and compliance
We introduced routine daily combination Lactobacillus and 
Bifidobacterium probiotics for prophylaxis of NEC in high- risk 
babies resident in our NICU on 1 January 2013, and for all 
eligible infants subsequently admitted.14 Written parental infor-
mation was provided.15 We administered first probiotic dose 
with first colostrum feeds, ideally on postnatal day 1. Probiotics 
continued until ~34 weeks postmenstrual age. We initially used 
the dual- species probiotic Infloran capsules (Desma Healthcare, 
Chiasso, Switzerland), containing Lactobacillus acidophilus and 
Bifidobacterium bifidum, half a capsule (125 mg) twice daily 
(1×109 colony- forming units (CFU) of each bacterial species 
daily). From April 2016, we used triple- species Labinic Drops 
(Biofloratech, Walton- on- Thames, UK), four drops once daily 
(~0.5×109 CFU dosage each of L. acidophilus, B. bifidum and B. 
longum subspecies infantis daily). Probiotic batches were subject 
to quality control (LJH’s laboratory) for species and CFU confir-
mation alongside our prospective microbiota study.16 Probiotics 
were prescribed on drug charts in accordance with our NICU’s 
guideline, and compliance was good.17
Oxygen saturation limits
Between 2008 and May 2011, we targeted oxygen saturation 
(SaO2) range 84%–92% for babies aged <32 weeks. From 31 
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Figure 1 The cumulative incidence of necrotising enterocolitis (NEC) from date of birth stratified by epoch. Risk table shows the number of cases 
still at risk with each passing week from birth, as well as the cumulative numbers of those diagnosed with NEC, who died without a diagnosis of 
NEC, or who were discharged home without a diagnosis of NEC. One NEC case was censored in this time- to- event analysis, a baby born in the month 
before 1 January 2013 who developed NEC after that date, leaving 34 cases in the pre- probiotics epoch and 16 cases in the routine probiotics epoch 
included.
May 2011, with emergent evidence associating lower SaO2 
ranges with mortality and NEC,18 we targeted 91%–95% SaO2.
Identification and classification of neC cases
From BadgerNet electronic patient records (CleverMed, UK), we 
identified all cases of definite, suspected, and perforated NEC. 
All eligible infants were screened between admission and final 
discharge home (or death if earlier) from either our NICU/paedi-
atric ward, or step- down NICU/other hospital ward if trans-
ferred out. Electronic clinical records, including X- ray request 
forms, abdominal radiographs, radiologist reports, blood results, 
surgical notes, histopathology and autopsy reports, and death 
certificates were independently reviewed by two unblinded 
clinicians (CR, PC) to determine whether they met NEC case 
definition according to each of three diagnostic systems: modi-
fied Bell’s staging criteria,19 Vermont- Oxford Network,20 and 
Battersby et al.1 We defined ‘surgical NEC’ as any baby with 
definite NEC in whom an abdominal drain was inserted or who 
underwent laparotomy. Potential surgical NEC cases whose 
operative findings and/or histopathology reports were uncertain 
or required expert interpretation, and also those with uncer-
tainty regarding staging, were additionally reviewed and adjudi-
cated by a consultant paediatric surgeon (AM) blinded to epoch.
We imputed as either NEC Bell’s stage 2b/3a cases babies 
who had acute clinical deterioration with Bell’s stage 2 or 3 
systemic and gastrointestinal signs (eg, blood in stool, abdom-
inal distension, tenderness, acidosis), but without classic stage 
2/3 radiographic findings of pneumatosis intestinalis, portal 
venous gas or pneumoperitoneum, provided treated clinically 
as presumed NEC with ≥10 days’ antibiotics and nil enter-
ally and with fixed distended loops, definite ascites or gasless 
abdomen on abdominal X- ray and no alternative diagnosis 
(eg, sepsis) for the episode. These included babies who under-
went surgical drain placement who died before planned lapa-
rotomy without autopsy, but with NEC recorded on their death 
certificate.
Isolated pneumoperitoneum without other clinical/radio-
graphic evidence of NEC was diagnosed as spontaneous intes-
tinal perforation, not NEC. Similarly, any case who satisfied any 
staging/clinical- radiological definition of NEC but who at prox-
imate surgery or postmortem examination for that episode had 
no NEC findings was excluded as NEC.
Identification and classification of late-onset sepsis
Late- onset sepsis was defined as clinical signs of sepsis and a 
concomitant positive blood or cerebrospinal fluid culture occur-
ring >72 hours after birth and before 46 weeks’ postmenstrual 
age or discharge/transfer from our NICU if sooner. We reviewed 
all positive blood and CSF cultures from our local microbi-
ology laboratory database for the whole study period. Repeated 
growth of the same isolate in successive samples obtained within 
7 days was considered the same episode.
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Figure 2 (A) Cumulative incidence of necrotising enterocolitis (NEC) 
stratified by gestational age at birth and by epoch. (B) Cumulative 
incidence of NEC stratified by gestational age at birth and by milk 
type for those who initiated enteral feeds. There was no case of NEC 
among those fed donor breast milk exclusively and so this group is not 
shown. (C) Cumulative incidence of mortality up to 200 days after birth, 
stratified by epoch and gestational age.
Table 2 Multivariable regression showing the relative risk of NEC 
associated with each factor
Factor Level Sub- hR (95% CI) P value
Epoch Routine vs pre- 
probiotics
0.44* (0.23 to 0.85) 0.014
Gestational age 
at birth
<25 weeks 1.00 (ref)
25–26 weeks 0.34** (0.16 to 0.70) 0.003
27–30 weeks 0.09*** (0.03 to 0.26) <0.001
≥31 weeks – –
Milk type† Mother's milk 1.00 (ref)
No enteral feed 0.15** (0.04 to 0.52) 0.003
Donor milk – –
Formula feed 0.85 (0.29 to 2.52) 0.775
Mixed 0.82 (0.41 to 1.64) 0.576
Birth weight <1000 g 1.00 (ref)
1000–1499 g 0.71 (0.26 to 1.99) 0.520
≥1500 g 1.12 (0.22 to 5.84) 0.891
Sex Male (vs female) 1.05 (0.59 to 1.86) 0.872
Antenatal steroids At least one dose (vs 
never)
1.10 (0.45 to 2.68) 0.840
NSAID None 1.00 (ref)
Indometacin 1.21 (0.47 to 3.08) 0.694
Ibuprofen 1.20 (0.41 to 3.56) 0.738
PROM No 1.00 (ref)
Yes 0.53 (0.22 to 1.29) 0.164
Not recorded 0.78 (0.33 to 1.88) 0.583
Mode of birth Caesarean (vs 
vaginal)
1.82 (0.92 to 3.60) 0.086
There were no cases of NEC among those fed using donor milk, or those born 
after 31 weeks in either epoch and so these groups are excluded from regression 
analysis.
*P<0.05, **p<0.01, ***p<0.001,
†Mode of milk feeding between first feed and full feeds or NEC/death if earlier.
NEC, necrotising enterocolitis; NSAID, non- steroidal anti- inflammatory drug; PROM, 
premature rupture of membranes; Ref., reference group; Sub- HR, sub- hazard ratio.
Outcome measures
NEC was coded as a binary outcome, and NEC case definition 
used for primary analyses was modified Bell’s criteria ≥2a.19 
Mortality from any cause was included as a secondary outcome.
Statistical analysis
Full details of statistical methods are provided in online supple-
mentary figure S1. In short, time- to- event analysis was used to 
estimate the difference in NEC rate between epochs, controlling 
for potentially confounding variables, and with death and 
discharge considered competing risks. Cumulative NEC inci-
dence is reported, with sub- hazard ratios (sub- HR: ratio of 
cumulative incidence rates) reflecting the association between 
each factor and cumulative incidence.
Effect of epoch appeared to vary significantly over the risk 
period, thus we conducted a second analysis including three 
separate coefficients for the effect of epoch on NEC in the first, 
second and beyond the second week after birth. A regression 
discontinuity analysis21 assessed whether the effect of epoch 
would be better explained by a linear trend over time or by a step 
change coinciding with introduction of probiotics. A time- to- 
event analysis estimated the effect of epoch on all- cause mortality. 
We used χ2 and Fisher’s exact tests to compare mortality rates 
following NEC diagnosis and other between- epoch proportions.
ReSuLTS
Descriptive analysis
The sample included 982 eligible neonates: 469 born in the 
pre- probiotics epoch and 513 in the routine probiotics epoch 
(online supplementary figure S2, patient flow). Table 1 shows 
comparative distributions of covariates between epochs. The 
only covariate to differ substantially between epochs was mode 
of milk feeding in the period up to full feeds: exclusive breast 
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Figure 3 The rate of necrotising enterocolitis (NEC) in each year (solid 
bars with error bars), and linear trends estimated within each era (lines 
with error bands). Each estimate is shown with a 95% bootstrapped 
confidence interval.
milk feeding was more common in the routine probiotics epoch 
(table 1).
neC incidence according to diagnostic system used
Table 1 shows NEC incidence in the pre- probiotics and routine 
probiotics epochs using the three NEC classifications. NEC 
Bell’s stage ≥2a occurred in 35 (7.5%) babies in the pre- 
probiotics epoch and 16 (3.1%) in the routine probiotics epoch. 
Imputed cases (without classical X- ray signs) were n=5 in the 
pre- probiotics epoch and n=1 in the routine probiotics epoch. 
In the latter era, three babies who developed NEC during the 
second postnatal week had not received prior probiotics; dosing 
had been overlooked in two cases. NEC rates within the routine 
probiotics epoch were similar irrespective of product used (10 
cases during 39 months using Infloran; 6 cases during 21 months 
using Labinic). More NEC cases of Bell’s stage ≥3a occurred 
in the pre- probiotics era, 29 (6.2%) vs 14 (2.7%) (p=0.017), 
but comprised a similar proportion of overall NEC cases within 
epochs, 29/35 (83%) vs 14/16 (88%) (p=0.70). Surgical NEC 
occurred in 30 infants in the pre- probiotics epoch (6.4% of 
eligible neonates) vs 15 (2.9%) in the routine probiotics epoch 
(p=0.014).
Cumulative incidence of neC from birth
Figure 1 shows the cumulative incidence of NEC from day of 
birth until final discharge home (or earlier death). NEC inci-
dence was strongly associated with birth gestational age (GA) 
(figure 2). Irrespective of GA, all cases of NEC occurred within 
40 days of birth. NEC rate was lower in the routine probiot-
ic- use era for all GA subgroups, with differences particularly 
pronounced in the first 2 weeks after birth.
The overall sub- HR for being born in the routine probiotics 
compared with pre- probiotics epoch on NEC rate was 0.43 
(95% CI 0.23 to 0.77, p=0.005). When all other covariates were 
included in the model (table 2), the estimated association between 
epoch and NEC rate remained very similar (sub- HR=0.44, 
95% CI 0.23 to 0.85, p=0.014). However, as reflected in the 
cumulative incidence curve, the difference between epochs was 
greatest in the first week after birth, and there was no difference 
after the second week (test for proportional hazard vs difference 
in sub- HR over time since birth: p=0.013). Estimates for the 
association between NEC and probiotics stratified by time since 
birth are shown in online supplementary table S3. In the first 
week after birth, the sub- HR for routine versus no probiotics 
was 0.08 (95% CI 0.01 to 0.59, p=0.014), in the second week 
was 0.43 (95% CI 0.13 to 1.4, p=0.17) and thereafter was 0.85 
(95% CI 0.36 to 2.0, p=0.72).
NEC was also independently linked to GA, and appeared 
less common before initiation of enteral feeds. There was no 
evidence that birth weight (once adjusted for GA) or milk type 
used for feeding were significantly associated with NEC rates, 
although our study was not designed to test these associations.
All-cause mortality and neC-associated rate of death within 
epochs
There were 67 deaths from all causes before discharge in the 
pre- probiotics epoch (14.3% of eligible neonates) and 47 in the 
routine probiotics epoch (9.2%). The cumulative incidence of 
death among eligible included babies is shown in figure 2, strat-
ified by epoch and GA. All- cause mortality reduced between 
epochs (sub- HR=0.62, 95% CI 0.42 to 0.90, p=0.013). This 
was attenuated and no longer statistically significant after 
adjusting for all covariates (online supplementary table S4). 
However, as with NEC, the proportional hazard assumption 
was not met and on stratifying by time since birth there was a 
significantly lower death rate beyond 2 weeks during the routine 
probiotics epoch compared with in the pre- probiotics epoch 
(sub- HR=0.34, 95% CI 0.17 to 0.68, p=0.003; online supple-
mentary table S5). Other factors independently associated with 
mortality were lower GA, never having received any enteral milk 
feeds, and non- reception of antenatal steroids.
Death before discharge among diagnosed NEC cases occurred 
in 15/35 (44%) in the pre- probiotics epoch, compared with 3/16 
(19%) in the routine probiotics epoch, p=0.15.
Regression discontinuity analysis
Within individual years across the whole study period, the 
proportion of NEC cases as a proportion of all eligible admis-
sions is shown in figure 3, along with estimates of the trend 
across years within each epoch. After adjusting for calendar year 
as a continuous variable in the time- to- event analysis, the effect 
of epoch was largely unchanged and remained statistically signif-
icant in the first week after birth (online supplementary table 
S3). This suggests that our results are not explained by an under-
lying linear improvement in NEC rates with time, but rather 
reflect a step change in incidence around the introduction of 
routine probiotics administration. Conversely, the improvement 
in death rate between epochs is better explained by a linear trend 
over time (online supplementary table S5).
Sensitivity analyses
Estimates were similar when postmenstrual age was used as a 
time- scale instead of days since birth (data not shown). Since 
milk type used between first and full feeds was the only other 
recorded variable to change significantly between epochs, we also 
stratified plots by mode of milk feed (among those who initiated 
enteral feeds) (figure 2); this showed a clear reduction in NEC 
rate in the routine probiotics epoch irrespective of milk feed 
type. Replacing ‘birth weight’ with ‘small for gestational age’ in 
the multivariable analysis did not affect findings. Repeating anal-
yses using the Vermont- Oxford Network NEC case definition20 
did not significantly affect findings either: the estimate of effect 
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of epoch was sub- HR=0.47 (95% CI 0.24 to 0.92, p=0.027), 
and the stratified analysis was also largely consistent. The only 
difference was in the regression discontinuity analysis, where the 
evidence was less strong that the trend was due to probiotics 
introduction as opposed to a linear trend (in the first week after 
birth, adjusted sub- HR=0.09, 95% CI 0.00 to 1.62, p=0.10), 
although this involved a very small number and was still consis-
tent with a big drop in NEC rate in the first week after birth.
Incidence of late-onset sepsis
Babies having one or more episodes of late- onset sepsis were 
significantly fewer in the routine probiotics epoch compared 
with the previous epoch (p<0.0001), and there were fewer 
episodes of coagulase- negative staphylococcal sepsis (p<0.0001) 
(table 1).
No case of any probiotic- organism bacterial sepsis was 
observed in either epoch.
DISCuSSIOn
Summary of findings
In this sample of 982 high- risk neonates admitted to our NICU 
over a 10- year period, NEC rate fell by more than half (from 
7.5% to 3.1%) in the 5- year period following the introduction of 
a policy of routine multispecies probiotics administration from 
birth (~55% relative risk reduction). Our apparent more- than 
halving of NEC risk with probiotics mirrors remarkably the 
highly significant risk reductions shown in large meta- analyses 
of RCTs and observational studies,7–11 including that of a very 
large German observational study which also used Infloran.22 
While some quality improvements occurred in our NICU over 
the study period, the difference observed was not attributable 
to changes in the main important covariates assessed between 
epochs, including exposure to breast milk. The improvement 
affected all high- risk neonates irrespective of GA. The impact 
appeared greatest in the first 2 weeks after birth, suggesting that 
aiming for very early postnatal probiotic bacterial gut colonisa-
tion is crucial. Late- onset sepsis rates also halved in the routine 
probiotics epoch compared with in the previous epoch (from 
22.6% to 11.5%). There was a fall in the all- cause mortality 
rate between epochs, although this was more consistent with a 
continuous trend over the study period.
Strengths and limitations
This is the first UK study to evaluate the potential impact of 
routine probiotics use on NEC rates. We used multispecies 
Lactobacillus and Bifidobacterium probiotics, shown to be most 
effective for NEC prophylaxis in large meta- analysis.11 These 
were routinely available, and commercially produced to the same 
accredited Good Manufacturing Practice standards required for 
drug production. We had a high rate of compliance and early 
probiotics administration in eligible babies. We applied three 
different NEC classification systems; all showed similar reduc-
tions in NEC rates across epochs. A further study strength is the 
variety of rigorous statistical analyses applied.
Being retrospective and observational, our findings only 
support an association and cannot conclusively determine that 
probiotics caused the observed markedly reduced NEC inci-
dence; unmeasured confounders might underlie observed differ-
ences between epochs. The only measured covariate observed 
to change between epochs was milk- type used, but this did 
not explain the improved NEC rate. Furthermore, a regres-
sion discontinuity analysis suggested that the drop in NEC 
rate was better explained by a step- change at the introduction 
of probiotics, and no other significant policy changes occurred 
between epochs that could have affected NEC incidence so 
markedly.
Importantly, colonisation and development of the early life 
microbiota, including Bifidobacterium and Lactobacillus species, 
occurs immediately postbirth. Previous studies (clinical and 
preclinical) indicate that optimal colonisation by supplemented 
species in a ‘naïve’ gut environment enables more effective 
persistence, linking to improved short- term and long- term host 
health.23–25
Choice of bacterial species and strains is a crucial consider-
ation. Many previous studies already highlighted that strains 
of species B. bifidum, B. longum subspecies infantis, and L. 
acidophilus were efficacious in other NICUs globally, key to our 
selecting these combinations for routine use.
Mechanistically, B. bifidum and B. infantis strains are pioneer 
colonisers of the infant gut, and their innate ability to digest 
components of breast milk preferentially, for example, human 
milk oligosaccharides (HMOs), augments their establishment 
within the infant gut.26 27 Numerous studies have shown how 
these species may provide resistance to potentially pathogenic 
microbes, so- called ‘colonisation resistance’, and also aid devel-
opment of the mucosal and systemic immune systems, key bene-
ficial traits to enhance development of the preterm gut and 
prevent NEC and late- onset sepsis.25 28 Furthermore, a multispe-
cies approach may promote better colonisation because Lacto-
bacillus may serve to reduce the oxygen content in the neonatal 
gastrointestinal tract, facilitating colonisation and persistence 
of anaerobic (ie, oxygen sensitive) Bifidobacterium species.24 
However, it is critical to note that there are significant differ-
ences between individual Bifidobacterium and Lactobacillus 
species and also huge strain variability, not least in ability to 
digest dietary components such as HMOs and in their immune 
and infection modulatory traits. Such complexities may explain 
conflicting results of some previous RCTs, such as the large UK 
multicentre Probiotics in Preterm infants Study (the PiPS trial) 
which—using the single- strain probiotic B. breve BBG-001—did 
not reduce NEC or late- onset sepsis.29 Those findings may link 
to poor colonisation ability of the selected B. breve BBG-001 
strain,30 compounded by low dosage used,31 and inability of this 
strain to digest key early life dietary components. B. breve strains 
frequently lack the genes required to assimilate HMO mole-
cules, and consequently have limited ability to assimilate HMOs 
compared with B. infantis and B. bifidum.32 Further studies are 
needed to determine the generalisability of the underlying poten-
tial benefits of multispecies probiotics in this at- risk cohort.
COnCLuSIOn
Administration of multispecies Lactobacillus and Bifidobac-
terium combination probiotics has been associated with a 
significantly decreased risk of NEC and late- onset sepsis in our 
NICU. This evaluation supports our routine use of multi- species 
Lactobacillus and Bifidobacterium combination probiotics for 
preventing NEC in very preterm neonates.
Author affiliations
1Neonatal Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, 
Norwich, UK
2Gut Microbes and Health, Quadram Institute Bioscience, Norwich, UK
3Core Science Resources, Quadram Institute Bioscience, Norwich, UK
4Norwich Medical School, University of East Anglia, Norwich, UK
5Paediatric and Neonatal Surgery, Jenny Lind Children’s Hospital, Norfolk and 
Norwich University Hospitals NHS Foundation Trust, Norwich, UK
Twitter Paul Clarke @drpaulclarke
Anglia. Protected by copyright.
 o
n
 N
ovem
ber 15, 2019 at University of East
http://fn.bmj.com/
Arch D
is Child Fetal Neonatal Ed: first published as 10.1136/archdischild-2019-317346 on 30 O
ctober 2019. Downloaded from
 
F7Robertson C, et al. Arch Dis Child Fetal Neonatal Ed 2019;0:F1–F7. doi:10.1136/fetalneonatal-2019-317346
Original article
Acknowledgements The authors would like to thank the following colleagues 
for their support of the initiative: Dr Mary- Anne Morris and the Jenny Lind 
Nutritional Support Team, all neonatal nursing, medical, and surgical colleagues, Dr 
Catherine Tremlett (microbiologist), Colin Green (pharmacist), Dr Tarnya Marshall 
(Chair of the Trust’s Drug, Therapeutics & Medicines Management Committee) 
and Julie Dawson (R+D Services Manager). The authors would also like to thank 
the anonymous reviewers for helpful comments and suggestions on the earlier 
manuscript version.
Contributors PC devised the study. CR, JJ, RC, HM, EB and PC collected the 
data. CR, PC and AM adjudicated NEC cases. GMS provided statistical expertise 
and analysed the data. CR, GMS, LJH and PC wrote the first manuscript draft and 
PC wrote the final draft. LJH provided intellectual input. All authors contributed to 
manuscript revisions and approved the final version. PC is guarantor.
Funding This work was part funded by: a Wellcome Trust Investigator award to 
LJH (100974/C/13/Z); a BBSRC ISP grant for Gut Health and Food Safety to LJH (BB/
J004529/1); BBSRC ISP grants for Gut Microbes and Health BB/R012490/1 and its 
constituent project(s) (BBS/E/F/000PR10353 and BBS/E/F/000PR10355) to LJH. GMS 
was supported by the BBSRC Core Capability Grant BB/CCG1860/1. CR received a 
Bliss travel bursary sponsored by Chiesi, which supported conference presentation of 
data from this study.
Competing interests None declared.
Patient consent for publication Not required.
ethics approval This project was a registered clinical audit/service evaluation. It 
was reviewed by the R+D Services Manager of the Norfolk and Norwich University 
Hospitals NHS Foundation Trust and was considered exempt from requiring formal 
research ethics service approval.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available on reasonable request.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iD
Paul Clarke http:// orcid. org/ 0000- 0001- 6203- 7632
RefeRences
 1 Battersby C, Longford N, Costeloe K, et al. Development of a gestational age- 
specific case definition for neonatal necrotizing enterocolitis. JAMA Pediatr 
2017;171:256–63.
 2 Neu J, Pammi M. Pathogenesis of NEC: impact of an altered intestinal microbiome. 
Semin Perinatol 2017;41:29–35.
 3 Duley L, Uhm S, Oliver S, et al. Top 15 UK research priorities for preterm birth. The 
Lancet 2014;383:2041–2.
 4 Gordon PV, Swanson JR, MacQueen BC, et al. A critical question for NEC researchers: 
can we create a consensus definition of NEC that facilitates research progress? Semin 
Perinatol 2017;41:7–14.
 5 Berrington JE, Stewart CJ, Embleton ND, et al. Gut microbiota in preterm infants: 
assessment and relevance to health and disease. Arch Dis Child Fetal Neonatal Ed 
2013;98:F286–90.
 6 Hill C, Guarner F, Reid G, et al. The International scientific association for probiotics 
and prebiotics consensus statement on the scope and appropriate use of the term 
probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506–14.
 7 AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm 
infants. Cochrane Database Syst Rev 2014:CD005496.
 8 Olsen R, Greisen G, Schrøder M, et al. Prophylactic probiotics for preterm infants: 
a systematic review and meta- analysis of observational studies. Neonatology 
2016;109:105–12.
 9 Dermyshi E, Wang Y, Yan C, et al. The “Golden Age” of Probiotics: A Systematic Review 
and Meta- Analysis of Randomized and Observational Studies in Preterm Infants. 
Neonatology 2017;112:9–23.
 10 Wang Q, Dong J, Zhu Y. Probiotic supplement reduces risk of necrotizing enterocolitis 
and mortality in preterm very low- birth- weight infants: an updated meta- analysis of 
20 randomized, controlled trials. J Pediatr Surg 2012;47:241–8.
 11 Chang H- Y, Chen J- H, Chang J- H, et al. Multiple strains probiotics appear to be the 
most effective probiotics in the prevention of necrotizing enterocolitis and mortality: 
an updated meta- analysis. PLoS One 2017;12:e0171579.
 12 Duffield SD, Clarke P. Current use of probiotics to prevent necrotising enterocolitis. 
Arch Dis Child Fetal Neonatal Ed 2019;104:F228.
 13 van den Akker CHP, van Goudoever JB, Szajewska H, et al. Probiotics for preterm 
infants: a strain- specific systematic review and network meta- analysis. J Pediatr 
Gastroenterol Nutr 2018;67:103–22.
 14 Deshpande GC, Rao SC, Keil AD, et al. Evidence- Based guidelines for use of probiotics 
in preterm neonates. BMC Med 2011;9:92.
 15 Sesham R, Oddie S, Embleton ND, et al. Probiotics for preterm neonates: 
parents’ perspectives and present prevalence. Arch Dis Child Fetal Neonatal Ed 
2014;99:F345–345.
 16 Alcon- Giner C, Dalby M, Caim S, et al. Microbiota supplementation with 
Bifidobacterium and Lactobacillus modifies the preterm infant gut microbiota and 
metabolome. bioRxiv 2019;698092.
 17 Brown E, Dabbour S, Clapuci R, et al. 4 years’ routine administration of probiotics to 
high- risk neonates: retrospective audit of adherence ot local guidelines. 7th Congress 
of the European Academy of Paediatrc Societies (EAPS) October 30- November 
3,2018; Paris, France. Available: https:// public- poster- links. s3. amazonaws. com/ EAPS- 
2018/ EAPS- 2018- EAPS8- 0834. pdf [Accessed 18 Oct 2019].
 18 Stenson B, Brocklehurst P, Tarnow- Mordi W, et al. Increased 36- week survival 
with high oxygen saturation target in extremely preterm infants. N Engl J Med 
2011;364:1680–2.
 19 Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging 
criteria. Pediatr Clin North Am 1986;33:179–201.
 20 Vermont Oxford Network. 2019 Manual of Operations, Part 2: Data Definitions & 
Infant Data Forms. Release 23.2, February 2019. Available: https:// vtoxford. zendesk. 
com/ hc/ en- us/ article_ attachments/ 360024732954/ Manual_ of_ Operations_ Part_ 2_ 
v23. 2. pdf [Accessed 18 Oct 2019].
 21 Thistlethwaite DL, Campbell DT. Regression- discontinuity analysis: an alternative to 
the ex post FACTo experiment. J Educ Psychol 1960;51:309–17.
 22 Denkel LA, Schwab F, Garten L, et al. Protective effect of Dual- Strain probiotics in 
preterm infants: a multi- center time series analysis. PLoS One 2016;11:e0158136.
 23 Houghteling PD, Walker WA. Why is initial bacterial colonization of the intestine 
important to Infantsʼ and Childrenʼs health? J Pediatr Gastroenterol Nutr 
2015;60:294–307.
 24 Koskella B, Hall LJ, Metcalf CJE. The microbiome beyond the horizon of ecological and 
evolutionary theory. Nat Ecol Evol 2017;1:1606–15.
 25 O’Neill I, Schofield Z, Hall LJ. Exploring the role of the microbiota member 
Bifidobacterium in modulating immune- linked diseases. Emerging Topics in Life 
Sciences 2017;1:333–49.
 26 Frese SA, Hutton AA, Contreras LN, et al. Persistence of Supplemented Bifidobacterium 
longum subsp. infantis EVC001 in Breastfed Infants. mSphere 2017;2:501–17.
 27 O’Callaghan A, van Sinderen D. Bifidobacteria and their role as members of the 
human gut microbiota. Front Microbiol 2016;7:925.
 28 Fukuda S, Toh H, Taylor TD, et al. Acetate- producing bifidobacteria protect the 
host from enteropathogenic infection via carbohydrate transporters. Gut Microbes 
2012;3:449–54.
 29 Costeloe K, Hardy P, Juszczak E, et al. Bifidobacterium breve BBG-001 in very preterm 
infants: a randomised controlled phase 3 trial. The Lancet 2016;387:649–60.
 30 Millar M, Seale J, Greenland M, et al. The microbiome of infants recruited 
to a randomised placebo- controlled probiotic trial (PIPs trial). EBioMedicine 
2017;20:255–62.
 31 Deshpande G, Rao S, Athalye- Jape G, et al. Probiotics in very preterm infants: the PIPs 
trial. The Lancet 2016;388.
 32 Gotoh A, Katoh T, Sakanaka M, et al. Sharing of human milk oligosaccharides 
degradants within bifidobacterial communities in faecal cultures supplemented with 
Bifidobacterium bifidum. Sci Rep 2018;8:13958.
Anglia. Protected by copyright.
 o
n
 N
ovem
ber 15, 2019 at University of East
http://fn.bmj.com/
Arch D
is Child Fetal Neonatal Ed: first published as 10.1136/archdischild-2019-317346 on 30 O
ctober 2019. Downloaded from
 
